About Genome Medical Holding
Genome Medical Holding is a private company based in South San Francisco, California. It has reported $89,978,309 raised in three offerings on Form D since August 2018. Its chief executive is Jill Davies.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Sep 23, 2024 | $75,344,304fully sold | 14 | $5.3M | EquityRule 506(b) | Form D ↗ |
| Apr 6, 2020 | Jun 13, 2019amended Jul 10, 2020 | $14,410,805of $14.9M target | 21 | $686K | Equity, Series B Preferred Stock and the Common Stock issuable upon the conversion thereof.Rule 506(b) | Form D/A ↗1 earlier filing |
| May 31, 2018 | Aug 15, 2018 | $223,200fully sold | 1 | $223K | OptionsRule 506(b) | Form D ↗ |
| Total, three offerings | $89,978,309 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Genome Medical Holding's Form D filed Sep 23, 2024.
Earlier filings also listed Tim Howe (director, last listed Jul 2020), Stephen Bloch (director, last listed Jul 2020), Robert C. Green (director, last listed Jul 2020), Randal W. Scott (director, last listed Jul 2020), Nicholas Naclerio (director, last listed Jul 2020), Minh Merchant (executive officer, last listed Jul 2020), Lisa J. Alderson (chief executive officer and director, last listed Jul 2020) and Kristin Ashcraft (executive officer, last listed Jul 2020).